Literature DB >> 25195647

Procalcitonin better than C-reactive protein, erythrocyte sedimentation rate, and white blood cell count in predicting DNAemia in patients with sepsis.

Christian Leli1, Angela Cardaccia, Marta Ferranti, Angelica Cesarini, Francesco D'Alò, Carla Ferri, Elio Cenci, Antonella Mencacci.   

Abstract

BACKGROUND: Procalcitonin (PCT) levels can be used to predict bacteremia and DNAemia in patients with sepsis. In this study, the diagnostic accuracy of PCT in predicting blood culture (BC) results and DNAemia, as detected by real-time PCR (RT-PCR), was compared with that of other markers of inflammation commonly evaluated in patients with suspected sepsis, such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and white blood cell (WBC) count.
METHODS: A total of 571 patients for whom BC, blood RT-PCR, PCT, CRP, ESR, and WBC count were requested for laboratory diagnosis of sepsis were included in the study. Receiver operating characteristic curve analysis was performed to compare the ability of the above biomarkers to predict BC and blood RT-PCR results.
RESULTS: A total of 108 pathogens were identified by BC (79 pathogens, 14.5% positive rate) and/or RT-PCR (90 pathogens, 16.5% positive rate), after exclusion of 26 contaminated samples. The PCT areas under the curve (AUCs) in predicting BC (0.843; 95% CI 0.796-0.890; p < 0.0001) and RT-PCR (0.916; 95% CI 0.888-0.945; p < 0.0001) results were significantly greater than AUCs found for CRP, ESR, and WBC count.
CONCLUSIONS: PCT showed a better diagnostic accuracy than CRP, ESR, and WBC count in predicting DNAemia and bacteremia in patients with suspected sepsis.

Entities:  

Keywords:  C-reactive protein; erythrocyte sedimentation rate; procalcitonin; real-time PCR; sepsis

Mesh:

Substances:

Year:  2014        PMID: 25195647     DOI: 10.3109/00365548.2014.936493

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  8 in total

Review 1.  The dormant blood microbiome in chronic, inflammatory diseases.

Authors:  Marnie Potgieter; Janette Bester; Douglas B Kell; Etheresia Pretorius
Journal:  FEMS Microbiol Rev       Date:  2015-05-03       Impact factor: 16.408

Review 2.  Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock.

Authors:  Brenda Ng Andriolo; Regis B Andriolo; Reinaldo Salomão; Álvaro N Atallah
Journal:  Cochrane Database Syst Rev       Date:  2017-01-18

3.  Diagnostic values of red cell distribution width, platelet distribution width and neutrophil-lymphocyte count ratio for sepsis.

Authors:  Hui-Bing Zhang; Juan Chen; Qiao-Fen Lan; Xiong-Jian Ma; Shi-Yan Zhang
Journal:  Exp Ther Med       Date:  2016-08-10       Impact factor: 2.447

4.  Procalcitonin and C-reactive protein in early diagnosis of sepsis caused by either Gram-negative or Gram-positive bacteria.

Authors:  H H Liu; M W Zhang; J B Guo; J Li; L Su
Journal:  Ir J Med Sci       Date:  2016-05-02       Impact factor: 1.568

5.  Evaluation of the Septifast MGrade Test on Standard Care Wards--A Cohort Study.

Authors:  Franz Ratzinger; Irene Tsirkinidou; Helmuth Haslacher; Thomas Perkmann; Klaus G Schmetterer; Dieter Mitteregger; Athanasios Makristathis; Heinz Burgmann
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

6.  Procalcitonin-guided antibiotic therapy in critically ill adults: a meta-analysis.

Authors:  Tao Zhang; Yan Wang; Qianting Yang; Yalin Dong
Journal:  BMC Infect Dis       Date:  2017-07-24       Impact factor: 3.090

Review 7.  Sepsis: From Pathophysiology to Individualized Patient Care.

Authors:  Ildikó László; Domonkos Trásy; Zsolt Molnár; János Fazakas
Journal:  J Immunol Res       Date:  2015-07-15       Impact factor: 4.818

8.  Diagnostic value of serum procalcitonin, lactate, and high-sensitivity C-reactive protein for predicting bacteremia in adult patients in the emergency department.

Authors:  Chiung-Tsung Lin; Jang-Jih Lu; Yu-Ching Chen; Victor C Kok; Jorng-Tzong Horng
Journal:  PeerJ       Date:  2017-11-27       Impact factor: 2.984

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.